secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-05-17T23:59:59+00:00
Accession:  0001193125-23-146584
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan reports preliminary Phase 1 data for TSC-100/101; TSC-101 advances to Dose Level 2
--------------------------------------------------------------------------------

- TSC-101 in high-risk MDS patient: 100% donor chimerism, no p53 mutation detected (sensitivity 0.01%), no DLTs.
- TSC-100 in T-cell ALL patient showed T cell expansion with activation markers on Day 7 post-infusion.
- Study advancing TSC-101 to Dose Level 2; RP2D and interim data expected by end of 2023.
- Two control patients with MDS had incomplete donor chimerism; one in early relapse.
- Phase 1 trial design includes three dose levels; second dose at DL2 and DL3 for both candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523146584/0001193125-23-146584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523146584/d490821d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-146584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer